Participants With Advanced Or Recurrent Endometrial Carcinoma clinical trials

Explore recruiting participants with advanced or recurrent endometrial carcinoma clinical trials.

Recruiting participants with advanced or recurrent endometrial carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Participants With Advanced Or Recurrent Endometrial Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)

Ireland, Austria, Italy, Spain, Belgium, Germany +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Participants With Advanced Or Recurrent Endometrial Carcinoma trials by city

Participants With Advanced Or Recurrent Endometrial Carcinoma in Toronto Participants With Advanced Or Recurrent Endometrial Carcinoma in Vancouver Participants With Advanced Or Recurrent Endometrial Carcinoma in Montreal Participants With Advanced Or Recurrent Endometrial Carcinoma in Calgary Participants With Advanced Or Recurrent Endometrial Carcinoma in Edmonton Participants With Advanced Or Recurrent Endometrial Carcinoma in Ottawa Participants With Advanced Or Recurrent Endometrial Carcinoma in Winnipeg Participants With Advanced Or Recurrent Endometrial Carcinoma in Quebec City Participants With Advanced Or Recurrent Endometrial Carcinoma in Hamilton Participants With Advanced Or Recurrent Endometrial Carcinoma in Kitchener Participants With Advanced Or Recurrent Endometrial Carcinoma in London Participants With Advanced Or Recurrent Endometrial Carcinoma in Halifax Participants With Advanced Or Recurrent Endometrial Carcinoma in New York Participants With Advanced Or Recurrent Endometrial Carcinoma in Los Angeles Participants With Advanced Or Recurrent Endometrial Carcinoma in Chicago Participants With Advanced Or Recurrent Endometrial Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease